Medical Treatment in Covid-19: Changes in Post-treatment Laboratory Results and CT Findings

Abstract

Medical Treatment in Covid-19: Changes in Post-treatment Laboratory Results and CT Findings Objective: Today, the symptoms, imaging features and laboratory findings of the disease are known, but the treatment of the Coronavirus disease 2019 has not been clarified. In this study, we aim to investigate the efficacy of favipiravir in patients who do not need invasive mechanical ventilation, by examining the post-treatment laboratory and computed tomography findings compared to the hydroxychloroquine which removed from the treatment guide. Methods: In our study, 49 patients diagnosed with Coronavirus disease 2019 and treated with hydroxychloroquine and favipiravir were examined. The patients were divided into 3 groups according to their treatment modalities. The changes in the pre-and post-treatment laboratory findings and computed tomography imaging of the patients in these 3 groups were examined. Results: There was no statistically significant difference between the rates and types of lesion patterns observed on thorax computed tomography in the groups. The most common lesion pattern in each group was the presence of ground glass opacity + consolidation in 18 patients (81.8%) in the hydroxychloroquine group, 7 patients (70%) in the favipiravir group and 10 patients (58.8%) in the hydroxychloroquine + favipiravir group. In all 3 groups, there was a statistically significant improvement in C-reactive protein, ferritin, fibrinogen values and computed tomography scores after treatment and there was no statistically significant difference between drugs. Conclusion: In this study, we found no significant superiority of favipiravir in terms of changes in laboratory and computed tomography findings after treatment in Covid-19 patients who do not need intensive care compared to hydroxychloroquine.